Update shared on04 Aug 2025
Fair value Decreased 48%The sharp decline in Zynex’s price target is primarily driven by a shift from modest revenue growth to contraction alongside a higher discount rate, resulting in a revised fair value of $2.85.
What's in the News
- Steven Dyson appointed CEO, succeeding Thomas Sandgaard, who will continue as Chairman and Chair of the Technology Committee; Dyson brings over 25 years’ experience in medical technology and private equity.
- CFO Dan Moorhead resigned, effective August 29, 2025; a consulting agreement for transition is expected, and a search for his replacement is underway.
- Zynex experienced widespread removal from major Russell indexes, including the Russell 2000, 2500, 3000, and associated Growth and Small Cap benchmarks.
- The company conducted a workforce reduction impacting 14% of employees, aimed to achieve $5 million in annualized cost savings, unrelated to the ongoing temporary Tricare payment suspension.
- Zynex submitted a 510(k) application to the FDA for its NiCO™ noninvasive CO-oximeter, featuring advanced laser technology addressing pigmentation bias in pulse oximetry; the targeted market is projected to exceed $4.3 billion by 2027.
Valuation Changes
Summary of Valuation Changes for Zynex
- The Consensus Analyst Price Target has significantly fallen from $5.50 to $2.85.
- The Consensus Revenue Growth forecasts for Zynex has significantly fallen from 1.6% per annum to -5.9% per annum.
- The Discount Rate for Zynex has significantly risen from 9.03% to 11.05%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.